Impact of maternal use of asthma-controller therapy on perinatal outcomes

Background Asthma during pregnancy usually requires treatment with controller medications about which more safety information is needed. The objectives are to assess the impact of the use of long-acting β2-agonists (LABAs) and the dose of inhaled corticosteroids (ICSs) during pregnancy on the preval...

Full description

Saved in:

Bibliographic Details
Published in:	Thorax 2013-08, Vol.68 (8), p.724-730
Main Authors:	Cossette, Benoit, Forget, Amélie, Beauchesne, Marie-France, Rey, Évelyne, Lemière, Catherine, Larivée, Pierre, Battista, Marie-Claude, Blais, Lucie
Format:	Article
Language:	eng
Subjects:	Administration, Inhalation Adult Algorithms Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Asthma Asthma - drug therapy Asthma - epidemiology Birth weight Clinical Epidemiology Emergency medical care Female Follow-Up Studies Gestational Age Humans Infant, Low Birth Weight Infant, Newborn Male Maternal Exposure - adverse effects Pregnancy Pregnancy Complications - drug therapy Pregnancy Complications - epidemiology Premature birth Premature Birth - epidemiology Premature Birth - etiology Prevalence Quebec - epidemiology Retrospective Studies Risk Factors Steroids Womens health
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background Asthma during pregnancy usually requires treatment with controller medications about which more safety information is needed. The objectives are to assess the impact of the use of long-acting β2-agonists (LABAs) and the dose of inhaled corticosteroids (ICSs) during pregnancy on the prevalence of low birth weight (LBW), preterm birth (PB) and small for gestational age (SGA). Methods A cohort of women with asthma giving birth from 1998 to 2008 was constructed from Québec (Canada) administrative databases. LBW was defined as weight 125 μg/day (fluticasone-equivalent) were associated with a non-significant trend of increased LBW, PB and SGA. Conclusions Despite the possibility of residual confounding due to uncontrolled or more severe asthma or smoking status, the use of LABA and low to moderate doses of ICSs were not associated with increased prevalence of perinatal outcomes. Additional research on higher ICSs doses is required to better evaluate their safety during pregnancy.
ISSN:	0040-6376 1468-3296